Ion Beam Applications SA
Simon Marcelis has a diverse work experience. Simon started their career as a Flying/Field Engineer - Beam Physics at IBA in 2008. Simon then progressed to roles of Site Technical Manager, Project Manager, and Product Manager at IBA. Simon also worked as a Sustainability Ambassador at IBA Dosimetry, where they were responsible for defining programs and objectives related to sustainability. Simon also had a role as a Director -Particle Therapy Business Line at IBA. In addition to their work at IBA, Simon worked as a Craftsman at sowood.be in 2011. Simon also had a self-employed role as an Illusionist, where they performed magic shows for various events.
Simon Marcelis has a diverse education history. Simon pursued an International MBA from IAE Paris - Sorbonne Business School from 2013 to 2015. In 2023, they completed the Senior Leadership Programme at Vlerick Business School. Prior to these business-related studies, Simon earned a Master's degree in Electronics and Telecommunications from École polytechnique de Louvain - Louvain School of engineering, studying from 2002 to 2008. Additionally, they studied Telecommunications Engineering at Czech Technical University in Prague from 2007 to 2008.
This person is not in the org chart
This person is not in any teams
Ion Beam Applications SA
4 followers
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.